Methadone and Buprenorphine-Associated Drug-Drug Interactions
Presenter: Andrew Saxon, MD, Professor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, and Director, Center of Excellence in Substance Addiction, Treatment, and Education, VA Puget Sound Healthcare System, Seattle WA
Fee: No Cost
Target Audience: The target audience for this module is primary care physicians.
This module reviews the following key data points which are important to primary care physicians: 1) the current epidemiologic data on drug-drug interactions between opioids and other medications, 2) possible explanations for increases in drug-drug interactions, 3) physiological and pharmacokinetic basis for adverse drug interactions, and 4) strategies for reducing risk for adverse drug interactions.
Core Competencies as a result of participating in this activity:
Interpersonal Skills and Communication
At the conclusion of this activity participants should be able to:
- Compare epidemiologic data on drug-drug interactions between opioids and other medications
- Review possible explanations for increases in drug-drug interactions an evidence-based approach in the use of opioids for low back pain
- Describe physiological and pharmacokinetic basis for adverse drug interactions
Identify strategies for reducing risk
Method of participating in the learning process:
In order to receive maximum credit, learners must:
1. Review the materials provided in this module.
2. Earn a minimum cumulative score of 80% on the post-test.
3. Complete an evaluation to assess satisfaction and plans for individual and/or team practice change.
4. Follow instructions at the end of the course regarding how to retrieve a certificate.*
*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
Accreditation and Certification of this activity:
Joint Accreditation Statement
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
In 2019, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB).
Release date: July 2, 2019 Date of Expiration: July 2, 2022
Physician Designation Statement
American Academy of Addiction Psychiatry designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAAP's interprofessional continuing education program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. During the planning process, anyone that is involved in the content is required to disclose to AAAP and our learners any real or potential conflict of interest related to the educational activity. The following individuals have no relevant financial relationships with an ACCME defined commercial interest to disclose: Thomas Penders, MD, Michael Goedde, MD, Nitigna Desai, MD, Karen Oliver, PhD, John Renner, Jr, MD, Kevin Sevarino, MD, PhD, Colleen LaBelle, MSN, RN-BC, CARN, Kathryn Cates-Wessel, Miriam Giles, Carol Johnson, Jennifer Lundstrom, and Justina Pereira. PCSS Clinical Expert Committee member Frances Levin, MD has nothing relevant to the content of this module to disclose. Content Developer Andrew Saxon, MD, has nothing to disclose.
Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Learners are advised that this activity may contain references to unlabeled uses of US FDA-approved products or to products not approved by the FDA for use in the United States. In these instances, participants will be made aware of such usage and discussions regarding either non–FDA-approved or investigational use of products/devices.
ADA Accommodation Statement
AAAP encourage persons with disabilities to participate in our programs and activities. If you anticipate needing any type of accommodation or have questions about this activity, please email firstname.lastname@example.org.
Privacy and Confidentiality Policy
AAAP values your privacy and confidentiality of the information you choose to share with us. Personal information collected from evaluations will not be shared with third parties.
Disclaimer: The views, opinions, and content expressed herein do not necessarily reflect the views or policies of AAAP, CSAT, SAMHSA, or HHS. No official support of or endorsement by AAAP, CSAT, SAMHSA, or HHS for these opinions or for particular instruments, software, or resources is intended or should be inferred.
Support for the Program:
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.